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OBJECTIVE—The term “receptor-associated prorenin sys-
tem” (RAPS) refers to the pathogenic mechanisms whereby
prorenin binding to its receptor dually activates the tissue
renin-angiotensin system (RAS) and RAS-independent intra-
cellular signaling via the receptor. The aim of the present
study was to deﬁne the association of the RAPS with diabetes-
induced retinal inﬂammation.
RESEARCH DESIGN AND METHODS—Long-Evans rats,
C57BL/6 mice, and angiotensin II type 1 receptor (AT1-R)-
deﬁcient mice with streptozotocin-induced diabetes were treated
with (pro)renin receptor blocker (PRRB). Retinal mRNA expres-
sion of prorenin and the (pro)renin receptor was examined by
quantitative RT-PCR. Leukocyte adhesion to the retinal vascula-
ture was evaluated with a concanavalin A lectin perfusion–
labeling technique. Retinal protein levels of vascular endothelial
growth factor (VEGF) and intercellular adhesion molecule
(ICAM)-1 were examined by ELISA. Retinal extracellular signal–
regulated kinase (ERK) activation was analyzed by Western
blotting.
RESULTS—Induction of diabetes led to signiﬁcant increase in
retinal expression of prorenin but not the (pro)renin receptor.
Retinal adherent leukocytes were signiﬁcantly suppressed with
PRRB. Administration of PRRB inhibited diabetes-induced reti-
nal expression of VEGF and ICAM-1. To clarify the role of signal
transduction via the (pro)renin receptor in the diabetic retina, we
used AT1-R–deﬁcient mice in which the RAS was deactivated.
Retinal adherent leukocytes in AT1-R–deﬁcient diabetic mice
were signiﬁcantly suppressed with PRRB. PRRB suppressed the
activation of ERK and the production of VEGF, but not ICAM-1,
in AT1-R–deﬁcient diabetic mice.
CONCLUSIONS—These results indicate a signiﬁcant contribu-
tion of the RAPS to the pathogenesis of diabetes-induced retinal
inﬂammation, suggesting the possibility of the (pro)renin recep-
tor as a novel molecular target for the treatment of diabetic
retinopathy. Diabetes 58:1625–1633, 2009
B
ecause the renin-angiotensin system (RAS) plays
an important role in the regulation of systemic
blood pressure, RAS inhibitors including angio-
tensin II type 1 receptor (AT1-R) blockers and
ACE inhibitors are safely and widely used in patients with
hypertension. In addition to strict control of blood glucose
levels, tight blood pressure control with RAS inhibition
has been shown to prevent the progression of diabetic
retinopathy in the UK Prospective Diabetes Study (UKPDS)
(1); however, diabetic patients are generally characterized
by low renin and high prorenin levels in the plasma,
indicating that the circulatory RAS is suppressed in diabe-
tes (2). Importantly, ACE inhibition resulted in signiﬁcant
suppression of the progression of retinopathy in normo-
tensive subjects with type 1 diabetes (3), suggesting that
the tissue RAS in the diabetic retina is activated indepen-
dently of the circulatory RAS, although the precise mech-
anism for activating the tissue RAS remains unclear.
The (pro)renin receptor, a recently identiﬁed transmem-
brane protein consisting of 350 amino acids, interacts with
prorenin to exert renin activity through the conforma-
tional change of the prorenin molecule instead of the
conventional proteolysis of the prorenin prosegment basi-
cally achieved by processing enzymes such as cathepsin B.
Given that the membrane-bound (pro)renin receptor is
reported to exist in the major organs but not in the
circulation (4), the nonproteolytic activation of prorenin is
hypothesized to play a critical role in the activation of the
tissue, but not the circulatory, RAS. In addition, prorenin
binding to its receptor is shown to cause RAS-independent
signal transduction via phosphorylation of extracellular
signal–regulated kinase (ERK)1/2 in cells bearing the
(pro)renin receptor (4–7). Thus, we proposed the nomen-
clature receptor-associated prorenin system (RAPS) for
the dual activation of the tissue RAS and RAS-independent
signaling pathway. In streptozotocin-induced diabetes,
blockade of prorenin binding to its receptor led to com-
plete suppression of proteinuria, glomerulosclerosis, and
renal production of angiotensin I and II without affecting
the circulatory RAS, indicating a critical contribution of
the RAPS to the pathogenesis of diabetic nephropathy
(6,8–10).
Recently, we have reported that AT1-R is expressed in
the ﬁbrovascular tissues surgically excised from human
eyes with proliferative diabetic retinopathy (11) and that
the tissue RAS is activated in the retina of mice with
streptozotocin-induced diabetes (12). Diabetic retinopathy
proved to be an inﬂammatory disorder depending on
vascular endothelial growth factor (VEGF) and intercellu-
lar adhesion molecule (ICAM)-1 (13–17). We have shown
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and angiogenic molecules is mediated by AT1-R signaling
and required for diabetes-induced retinal leukocyte adhe-
sion (12), indicating the association of the tissue RAS with
diabetic retinopathy. This is supported by several recent
reports showing that the RAS contributes to various
pathological vascular conditions including inﬂammation
and neovascularization via AT1-R signaling (18–21). How-
ever, the role of the (pro)renin receptor as a trigger to
activate the tissue RAS in diabetes-induced retinal inﬂam-
mation has not been deﬁned. Although we have further
shown that the tissue RAS for promoting retinal inﬂam-
mation (22) and neovascularization (23) is activated by
nonproteolytically processed prorenin, it has not been
determined whether (pro)renin receptor–mediated intra-
cellular signaling, the other pathway of the RAPS, is
pathogenic in the eye. In the present article, we report the
ﬁrst evidence of a signiﬁcant relationship between the
RAPS and diabetes-induced retinal inﬂammation together
with underlying molecular and cellular mechanisms.
RESEARCH DESIGN AND METHODS
Animals and induction of diabetes. Long-Evans rats (SLC, Shizuoka,
Japan), C57BL/6 mice (CLEA, Tokyo, Japan), and AT1-R–deﬁcient mice (24)
(based on the C57BL/6J strain and donated by Tanabe Seiyaku, Osaka, Japan)
aged 6–8 weeks were used. The mutant mice undergo targeted replacement of
AT1a-R (one of the two isoforms AT1a-R and AT1b-R in rodents) loci by lacZ
gene (24). All animal experiments were conducted in accordance with the
Association for Research in Vision and Ophthalmology Statement for the Use
of Animals in Ophthalmic and Vision Research. Animals received an intraperi-
toneal injection of 80 mg/kg body wt streptozotocin (Sigma, St. Louis, MO)
once for rats and for 3 consecutive days for mice. Animals with plasma
glucose levels 250 mg/dl 7 days after injection were considered diabetic.
Preparation of (pro)renin receptor blockers. To cover the handle region
(positions 11–15) of the prorenin molecule, which is the binding site of the
(pro)renin receptor (25), we designed decoy peptides NH2-RILLKKMPSV-
COOH (6,9,10,22,26) and NH2-IPLKKMPS-COOH (8,23) as rat and mouse
(pro)renin receptor blockers (PRRBs), respectively, and puriﬁed them by
high-performance liquid chromatography on a C-18 reverse-phase column as
previously described. We applied rat PRRB to diabetic rats (Figs. 1 and 2) and
mouse PRRB to diabetic mice (Figs. 3–7). The speciﬁc inhibitory action of
PRRB against prorenin binding with the (pro)renin receptor and subsequent
ERK activation has been conﬁrmed in our present (supplemental Figs. 1 and
2, available in an online appendix at http://diabetes.diabetesjournals.org/cgi/
content/full/db08-0254/DC1) and recent (27,28) in vitro data. The speciﬁc
inhibitory action of PRRB against the tissue RAS or RAPS in vivo was also
conﬁrmed in our recent data (6,8–10,22,23,26). As a negative control, rat
PRRB was inactivated by heat denaturation at 100°C for 10 min and used as
control peptide. We also generated a scramble peptide NH2-KPMLISKP-COOH
for mouse PRRB as another negative control.
Treatment with PRRB, control peptide, scramble peptide, or the AT1-R
blocker losartan. Diabetic animals were intraperitoneally injected with
vehicle (0.25% DMSO in PBS), 1.0 mg/kg control peptide, 1.0 mg/kg scramble
peptide, 0.1 or 1.0 mg/kg PRRB, or 20 mg/kg of the AT1-R blocker losartan
(Cayman Chemical, Ann Arbor, MI) daily for seven consecutive weeks
immediately after the establishment of diabetes (7 days after streptozotocin
injection) until the end of the study. Daily injection was based on our
preliminary experiments showing the time course of serum concentration of
PRRB injected into normal mice and measured by BIAcore 2000 (GE Health-
care Bio-Sciences KK, Tokyo, Japan) (supplemental Fig. 3). In our preliminary
experiments, 20 mg/kg losartan proved to be the maximal-effect dose for
inhibiting leukocyte adhesion to the retinal vessels of diabetic mice (data not
shown).
Quantiﬁcation of retinal adherent leukocytes. The retinal vasculature
and adherent leukocytes were imaged by perfusion labeling with ﬂuorescein
isothiocyanate (FITC)-coupled concanavalin A lectin (ConA) (Vector, Burlin-
game, CA), as previously described (29). After deep anesthesia, the chest
cavity was opened and a 20 or 27 G cannula (for rats or mice, respectively)
was introduced into the left ventricle. After injection of PBS to remove
erythrocytes and nonadherent leukocytes, 20 or 2 ml (for rats or mice,
respectively) of FITC-conjugated ConA was perfused. After the eyes were
enucleated, the retinas were ﬂat mounted. The ﬂat mounts were imaged using
an epiﬂuorescence microscope (IX71; Olympus, Tokyo, Japan), and the total
number of ConA-stained adherent leukocytes per retina was determined.
Quantitative RT-PCR analyses for prorenin and the (pro)renin recep-
tor. We isolated total RNA from the retina with an RNeasy Mini Kit (Qiagen,
Tokyo, Japan) and performed a real-time quantitative RT-PCR with the
TaqMan One-Step RT-PCR Master Mix Reagents Kit, an ABI Prism 7700 HT
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FIG. 1. Upregulation of prorenin expression and tissue localization of
prorenin and the (pro)renin receptor in the diabetic retina. A: Upregu-
lation of prorenin mRNA levels, analyzed by real-time RT-PCR, in the
retina by inducing diabetes (DM) (n  8). B: (Pro)renin receptor
mRNA levels were unchanged following induction of diabetes (n  8).
Immunostaining for non–proteolytically activated prorenin (C–E)
(green ﬂuorescence) and the (pro)renin receptor (F–H) (red ﬂuores-
cence) in retinal vessels. **P < 0.01. NS, nonsigniﬁcant. (A high-
quality digital representation of this ﬁgure is available in the online
issue.)
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primers for the rat genes that encode prorenin, the (pro)renin receptor, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as previously described
(9,10,26).
Immunohistochemistry for nonproteolytically activated prorenin and
the (pro)renin receptor. Rat eyes were ﬁxed with 4% paraformaldehyde and
embedded in parafﬁn. After deparafﬁnized sections were precoated with 4%
skim milk to block nonspeciﬁc binding, a rabbit polyclonal antibody against
the gate region of rat prorenin (1:100) or a goat polyclonal antibody against the
rat (pro)renin receptor (1:100) was applied as the primary antibody. An
antibody against the gate region binds only to nonproteolytically activated
prorenin but not to inactive prorenin or proteolytically activated prorenin (i.e.,
renin) (6). The anti-(pro)renin receptor antibody was raised by using the
previously established COS-7 cells producing rat (pro)renin receptor protein
(9). The sections were then incubated with a biotin-conjugated IgG as the
secondary antibody and TOTO-3 (1:500) (Molecular Probes, Eugene, OR) for
nuclear staining. The immunohistochemical reactions were visualized by
using a Vectastain ABC Standard Kit (Vector Laboratories, Burlingame, CA)
and Tyramide Signal Ampliﬁcation Fluorescein System (PerkinElmer, Boston,
MA) according to the manufacturer’s protocol. The samples were viewed with
the scanning laser confocal microscope.
Western blot analyses for phosphorylated and total forms of ERK1/2.
The isolated retina was placed into the lysis buffer. After blocking nonspeciﬁc
binding with 5% skim milk, polyvinylidene ﬂuoride membranes were incu-
bated with a mouse monoclonal antibody against phosphorylated ERK1/2
(1:1,000; Cell Signaling Technology, Beverly, MA), total ERK1/2 (1:1,000; Cell
Signaling Technology), or -tubulin (1:1,000; Sigma). Membranes were then
incubated with biotin-conjugated secondary antibody (Jackson Immuno-
Research Laboratories, West Grove, PA) followed by avidin-biotin complex
(Vectastain ABC Elite Kit; Vector Laboratories). Finally, the signals were
detected through enhanced chemiluminescence (ECL Blotting Analysis Sys-
tem; GE Healthcare).
Enzyme-linked immunosorbent assay for VEGF and ICAM-1. The iso-
lated retina was placed into the lysis buffer. The protein levels of VEGF and
ICAM-1 were determined with enzyme-linked immunosorbent assay (ELISA)
kits (R&D Systems). The tissue sample concentration was calculated from a
standard curve and corrected for protein concentration.
RESULTS
Metabolic parameters. Animals with streptozotocin-in-
duced diabetes showed a signiﬁcant decrease in body
weight (P  0.01) and a signiﬁcant increase in blood
glucose levels (P  0.01) compared with those in age-
matched nondiabetic controls (Table 1). Treatment with
PRRB did not signiﬁcantly change these metabolic param-
eters (P  0.05) (Table 1).
Prorenin mRNA expression was upregulated in the
diabetic retina. To elucidate the involvement of prorenin
and the (pro)renin receptor in the pathogenesis of diabetic
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FIG. 2. Inhibitory effect of PRRB on retinal leukocyte adhesion.
Flat-mounted retinas from normal (A) and diabetic (DM) rats treated
with vehicle (B), control peptide (CP) (C), or PRRB (D). Scale bars:
100 m. E: The number of retinal adherent leukocytes. PRRB-treated
diabetic rats showed signiﬁcantly fewer adherent leukocytes than did
vehicle- or control peptide-treated diabetic rats (n  5–13). *P < 0.05
and **P < 0.01. NS, nonsigniﬁcant. (A high-quality digital representa-
tion of this ﬁgure is available in the online issue.)
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FIG. 3. Inhibitory effect of PRRB on retinal expression of inﬂammatory
molecules. PRRB signiﬁcantly suppressed retinal protein levels of
VEGF (A) and ICAM-1 (B) analyzed by ELISA, both of which were
elevated after induction of diabetes (DM) (n  8–11). *P < 0.05 and
**P < 0.01.
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DIABETES, VOL. 58, JULY 2009 1627retinopathy, we ﬁrst performed quantitative RT-PCR anal-
yses for prorenin and the (pro)renin receptor in the retina.
Prorenin mRNA levels (ratio to GAPDH mRNA) were
upregulated (P  0.01) in the diabetic retina compared
with those in age-matched normal control rats (Fig. 1A). In
contrast, mRNA levels of the (pro)renin receptor showed
no signiﬁcant differences (P  0.05) between diabetic rats
and normal controls (Fig. 1B).
Diabetes-induced activation of prorenin colocalized
with the (pro)renin receptor was attenuated with
PRRB. Immunohistochemistry for normal, vehicle-, or
PRRB-treated diabetic rat eyes was performed to identify
the tissue localization of nonproteolytically activated pro-
renin and the (pro)renin receptor. Immunoreactivity of
activated prorenin in the retinal vessels was negligible in
nondiabetic controls (Fig. 1C), substantially enhanced in
diabetes (Fig. 1D), and abrogated by PRRB application to
the background signal (Fig. 1E). In contrast, immunoreac-
tivity of the (pro)renin receptor (Fig. 1F) was unaltered by
induction of diabetes (Fig. 1G) or treatment with PRRB
(Fig. 1H).
PRRB treatment suppressed diabetes-induced retinal
leukocyte adhesion. The retinal adherent leukocytes
were imaged by perfusion labeling with FITC-coupled
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FIG. 4. PRRB was more potent in inhibiting diabetes-induced retinal
leukocyte adhesion than the AT1-R blocker losartan. Flat-mounted
retinas from diabetic (DM) mice treated with vehicle (A), losartan (B),
PRRB (C), or losartan plus PRRB (D). Scale bars: 50 m. E: Compared
with losartan treatment, PRRB application led to signiﬁcant (P < 0.05)
suppression of leukocyte adhesion to the diabetic retinal vessels (n 
10–14). *P < 0.05. **P < 0.01. NS, nonsigniﬁcant; SP, scramble peptide.
(A high-quality digital representation of this ﬁgure is available in the
online issue.)
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FIG. 5. RAS-independent (pro)renin receptor–mediated intracellular
signaling contributes to diabetes-induced retinal leukocyte adhesion.
Flat-mounted retinas from nondiabetic (A) and diabetic (DM) AT1-R–
deﬁcient mice treated with vehicle (B) or PRRB (C). Scale bars: 100
m. D: The number of retinal adherent leukocytes. Compared with
diabetic wild-type (WT) animals, diabetic AT1-R–deﬁcient mice
exhibited a signiﬁcant reduction of the number of adherent leuko-
cytes. PRRB administration to diabetic AT1-R–deﬁcient mice showed
signiﬁcantly fewer adherent leukocytes than did vehicle administra-
tion (n  6–8). **P < 0.01. KO, knockout. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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retina from the posterior retina around the optic disc (Fig.
2A–D) to the peripheral (anterior) retina next to the ora
serrata. The total number of adherent leukocytes was
signiﬁcantly (P  0.01 for both) higher in vehicle-treated
(Fig. 2B) and control peptide-treated (Fig. 2C) diabetic
rats than in normal age-matched controls (Fig. 2A). PRRB-
treated diabetic rats (Fig. 2D) showed a signiﬁcant de-
crease in the leukocyte count in a dose-dependent fashion
compared with that in vehicle-treated (P  0.05) or control
peptide-treated (P  0.01) diabetic rats (Fig. 2E).
PRRB treatment suppressed diabetes-induced up-
regulation of retinal VEGF and ICAM-1 production.
Retinal protein levels of VEGF (Fig. 3A) and ICAM-1 (Fig.
3B) were signiﬁcantly (P  0.01) higher in vehicle-treated
diabetic mice than in age-matched normal controls. PRRB
signiﬁcantly suppressed retinal protein levels of these
inﬂammatory molecules known as pathogenic in the dia-
betic retina (Fig. 3A and B).
PRRB was more potent in inhibiting diabetes-induced
retinal leukocyte adhesion than the AT1-R blocker
losartan. We examined retinal leukocyte adhesion for
comparison among diabetic mice treated with vehicle,
scramble peptide, the AT1-R blocker losartan, PRRB, and
losartan plus PRRB. Compared with vehicle (Fig. 4A)o r
scramble peptide treatment, the inhibitory effect of PRRB
(71.3% inhibition) (Fig. 4C) on diabetic retinal inﬂamma-
tion was more potent than that of losartan alone (32.4%
inhibition) (Fig. 4B) and was equivalent to that of losartan
plus PRRB (Fig. 4D), showing that PRRB in combination
with losartan caused little or no additive effect compared
with PRRB alone (Fig. 4E). Thus, PRRB was suggested to
inhibit both angiotensin II–dependent (32.4% contribu-
tion) and –independent (71.3  32.4  38.9% contribution)
actions.
RAS-independent (pro)renin receptor signaling con-
tributed to diabetes-induced retinal leukocyte adhe-
sion. To clarify the role of RAS-independent intracellular
signaling via the (pro)renin receptor, we used mice in
which the RAS was deactivated by genetic ablation of
AT1-R. The number of adherent leukocytes in the retinal
vasculature was signiﬁcantly (P  0.01) higher in diabetic
wild-type mice than in nondiabetic wild-type controls.
Compared with diabetic wild-type animals, diabetic AT1-
R–deﬁcient mice exhibited a signiﬁcant (P  0.01; 27.3%)
reduction of the number of adherent leukocytes. Com-
pared with that in nondiabetic AT1-R–deﬁcient mice (Fig.
5A), induction of diabetes (Fig. 5B) signiﬁcantly (P  0.01)
increased the number of adherent leukocytes in the retinal
vasculature. The number of retinal adherent leukocytes
was signiﬁcantly (P  0.01; 46.6% of diabetic wild-type
mice) smaller in PRRB-treated diabetic AT1-R–deﬁcient
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FIG. 6. RAS-independent (pro)renin receptor–mediated intracellular
signaling contributes to ERK1/2 activation in the diabetic retina. A and
B: Western blotting for phosphorylated and total levels of ERK1/2 in
AT1-R–deﬁcient mice with diabetes (DM). PRRB suppressed relative
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treated diabetic AT1-R–deﬁcient mice (Fig. 5D). These
data with pharmacological blockade (Fig. 4) and genetic
ablation (Fig. 5) of AT1-R indicated dual contribution of
the tissue RAS (32.4 and 27.3%, respectively) and RAS-
independent (pro)renin receptor signaling (38.9 and 46.6%)
to diabetes-induced retinal inﬂammation.
RAS-independent (pro)renin receptor signaling con-
tributed to diabetes-induced activation of retinal
ERK1/2. To further determine whether RAS-independent
intracellular signaling via the (pro)renin receptor contrib-
utes to the activation of ERK1/2 in the diabetic retina,
phosphorylated ERK1/2 was examined in the retina from
AT1-R–deﬁcient diabetic mice. PRRB treatment sup-
pressed phosphorylated but not total ERK1/2 (Fig. 6A).
Relative phosphorylation of ERK1/2, increased by induc-
ing diabetes, was signiﬁcantly (P  0.01) suppressed by
PRRB application, whereas no signiﬁcant (P  0.05)
differences were detected in total ERK1/2 protein levels
(Fig. 6B).
RAS-independent (pro)renin receptor signaling con-
tributed to retinal expression of VEGF but not
ICAM-1. To examine whether RAS-independent intracel-
lular signaling via the (pro)renin receptor contributes to
the upregulation of the pathogenic molecules responsible
for diabetes-induced retinal inﬂammation (Fig. 3), diabetes
was induced in AT1-R–deﬁcient mice to measure retinal
levels of VEGF and ICAM-1 protein. Compared with that in
nondiabetic AT1-R–deﬁcient mice, retinal expression of
VEGF (P  0.01) (Fig. 7A) and ICAM-1 (P  0.05) (Fig. 7B)
was signiﬁcantly enhanced by diabetes induction. PRRB
application to AT1-R–deﬁcient diabetic mice led to signif-
icant suppression of VEGF (P  0.05) (Fig. 7A) but not
ICAM-1 (P  0.05) (Fig. 7B) compared with vehicle
treatment in AT1-R–deﬁcient diabetic mice.
DISCUSSION
The present study reveals for the ﬁrst time, to our knowl-
edge, several important ﬁndings concerning the role of the
(pro)renin receptor in diabetes-induced retinal inﬂammation.
First, induction of diabetes led to signiﬁcant upregulation of
prorenin expression in the retina, and diabetes-induced acti-
vation of prorenin colocalized with its receptor in the retinal
vessels was substantially attenuated with PRRB (Fig. 1).
Second, diabetes-induced leukocyte adhesion to the retinal
vasculature was suppressed by PRRB treatment, indicating
that prorenin binding with its receptor contributes to the
pathogenesis in the diabetic retina (Fig. 2). Third, the molec-
ular mechanisms in the suppression of retinal leukocyte
adhesion proved to include the inhibitory effects of PRRB on
the retinal expression of VEGF and ICAM-1, both of which
are known as key factors responsible for diabetes-induced
retinal inﬂammation (Fig. 3).
Recently, surgical sample data have revealed the ele-
vated levels of angiotensin II in the vitreous of eyes with
proliferative diabetic retinopathy (30) and diabetic macu-
lar edema (31). In accordance with the ﬁndings of these
clinical laboratory studies, we have shown that induction
of diabetes to mice led to a signiﬁcant increase in retinal
expression and production of the RAS components (12).
Although these ﬁndings indicated the association of the
tissue RAS with diabetic retinopathy, the precise mecha-
nism for activating the tissue RAS in the diabetic retina has
not been determined. In parallel, little has been known
about the bioactivity of the prorenin molecule per se other
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eral nephrectomy resulted in signiﬁcant decline of plasma
renin but not prorenin to an undetectable level, suggesting
that the proteolytic processing of prorenin to renin is
conﬁned to the kidney and that other organs including the
eye are capable of producing only prorenin, but not renin
(32,33). Elevated prorenin levels in the plasma of long-
standing diabetes (2,34,35) have indicated that prorenin
may be a hallmark of microvascular complications in
diabetes. Indeed, the vitreous levels of prorenin were
higher in eyes with proliferative diabetic retinopathy than
in those with nonproliferative retinopathy or without
retinopathy (36), suggesting the involvement of prorenin
with the pathogenesis of diabetic retinopathy. Reasonably,
retinal mRNA levels of prorenin were elevated following
induction of diabetes (Fig. 1A), whereas (pro)renin recep-
tor levels were unaltered (Fig. 1B). The observed ligand-
receptor expression change is compatible with our recent
data on diabetic nephropathy (9,10) and choroidal neovas-
cularization (37). These ﬁndings, in concert with the
immunohistochemical results (Fig. 1C–H), suggest the
signiﬁcance of the ligand-based regulation in the activation
of the RAPS. Importantly, nonproteolytically activated
prorenin was localized in diabetic retinal vessels bearing
the (pro)renin receptor (Fig. 1D and G), showing that the
initiating step of the tissue RAS is prepared in the diabetic
retina.
The molecular and cellular mechanisms underlying the
pathogenesis of diabetic retinopathy are not fully under-
stood; however, increasing evidence has suggested the
involvement of inﬂammatory processes including cytokine
upregulation and leukocyte inﬁltration, causing diabetic
retinopathy to be regarded as an inﬂammatory disease
(14,17,29,38,39). Retinal vasculature in diabetes is accom-
panied by inﬂammatory cell adhesion (40), which triggers
vascular hyperpermeability (14) and pathological neovas-
cularization (39). ICAM-1, constitutively expressed on
vascular endothelial cells at a low level, is swiftly upregu-
lated during inﬂammation, resulting in an enhancement of
leukocyte-endothelium interaction. Previous studies using
donor eyes from diabetic subjects (13) and experimentally
induced diabetes (14,29) demonstrated that retinal ICAM-1
expression was elevated together with leukocyte adhesion
and inﬁltration. Antibody-based blockade or genetic abla-
tion of ICAM-1 led to signiﬁcant suppression of vascular
hyperpermeability in early diabetes (14) or capillary loss in
established diabetes (38). VEGF, a potent angiogenic and
proinﬂammatory factor, plays a central role in the patho-
genesis of diabetic retinopathy. In patients with diabetic
retinopathy, VEGF levels in the intraocular ﬂuid were
increased not only during the proliferative stage (15) but
also during the nonproliferative stage characterized by
macular edema (16). Interestingly, angiotensin II levels are
elevated and correlated with VEGF levels in the vitreous
ﬂuid of patients with diabetic macular edema (31). Angio-
tensin II has been shown to induce ICAM-1 (41) and VEGF
(42) via AT1-R in previous in vivo and in vitro studies. Also
in the murine model of streptozotocin-induced diabetes,
we have recently shown that the tissue RAS enhanced
retinal expression of these inﬂammatory molecules and
subsequent leukocyte adhesion to the retinal vasculature,
all of which were suppressed by AT1-R blockade (12). In
concert with the previous data, the currently observed
PRRB-induced suppression of diabetes-induced retinal in-
ﬂammation (Figs. 2 and 3) indicates that the tissue RAS is
activated in the diabetic retina by (pro)renin receptor–
mediated nonproteolytic activation of prorenin, leading to
AT1-R signaling–mediated VEGF and ICAM-1 upregulation
and retinal leukocyte adhesion.
The present study further revealed the role of RAS-
independent (pro)renin receptor signaling in diabetes-
induced retinal inﬂammation. The use of two different
methods of inactivating AT1-R (Figs. 4 and 5) conﬁrmed
that PRRB functioned to inhibit both RAS-dependent and
-independent mechanisms underlying retinal leukocyte
adhesion. These data are the ﬁrst to show the involvement
of the RAPS, i.e., (pro)renin receptor–mediated signal
transduction and tissue RAS activation, in the pathogene-
sis of diabetic retinopathy. We have recently shown the
contribution of (pro)renin receptor signaling to diabetic
nephropathy using AT1-R–deﬁcient mice. AT1-R–deﬁcient
mice with streptozotocin-induced diabetes exhibited re-
duced proteinuria and glomerulosclerosis in the early
phase compared with wild-type mice with diabetes, indi-
cating a signiﬁcant role of the tissue RAS in diabetic
nephropathy. Surprisingly, these renal events in AT1-R–
deﬁcient diabetic mice later progressed to the equivalent
levels seen in wild-type diabetic mice (8). The glomerulo-
sclerosis observed in AT1-R–deﬁcient diabetic mice was
associated with ERK activation, which was completely
blocked together with the phenotype by sustained appli-
cation of PRRB, suggesting that the redundant pathways
of the RAPS were involved in the pathogenesis of diabetic
nephropathy (8). In addition, we administered PRRB to
AT1-R–deﬁcient diabetic mice and conﬁrmed the signiﬁ-
cant role of intracellular signaling via the (pro)renin
receptor in the diabetes-induced retinal leukocyte adhe-
sion (Fig. 5). Importantly, PRRB application to AT1-R–
deﬁcient diabetic mice led to signiﬁcant suppression of
ERK activation, a known key intracellular signaling via the
(pro)renin receptor (Fig. 6). Of diabetes-related inﬂamma-
tory molecules (the expression of which was inhibited by
PRRB [Fig. 3]), VEGF but not ICAM-1 was also regulated
by (pro)renin receptor signaling per se (Fig. 7). The data
are supported by and consistent with our recent report on
choroidal neovascularization showing that (pro)renin re-
ceptor signaling selectively induces VEGF and monocyte
chemoattractant protein-1 out of several inﬂammatory and
angiogenic molecules mediated by AT1-R (37). These new
ﬁndings (Figs. 4–7) clariﬁed molecular and cellular mech-
anisms mediated by RAS-independent intracellular signal-
ing via the (pro)renin receptor in diabetes-induced retinal
inﬂammation. In addition to our recent reports showing
that the RAPS contributes to glomerulosclerosis in the
kidney and ﬁbrosis in the heart (6–10,26), the present data
are the ﬁrst to show the association of the RAPS with
inﬂammation in the eye (Fig. 8).
In the present data, there was a discrepancy between in
vivo (Figs. 1–7 and supplemental Fig. 3) and in vitro
(supplemental Figs. 1–2) doses of PRRB. In vivo, intraperi-
toneal injection of PRRB at a dose of 1.0 mg  kg
1  day
1
led to a serum concentration of 110 ng/ml (100 nmol/l),
which was cleared within 24 h (supplemental Fig. 3).
Because the maximal concentration of PRRB in the serum
is 50–100 times higher than the physiological level of
endogenous prorenin (1–2 nmol/l), the currently used dose
of 1.0 mg  kg
1  day
1 is thought to be sufﬁcient to inhibit
the in vivo binding of prorenin to the receptor. Indeed, a
lower dose of 0.1 mg  kg
1  day
1 (presumably 10 nmol/l
in the serum [5–10 times higher than physiological prore-
nin]) was also effective (Fig. 2). In vitro, however, much
higher doses of PRRB (10–100 mol/l) were required to
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tal Fig. 2). This would be attributable at least in part to the
in vitro property of cellular localization of the (pro)renin
receptor. In cultured vascular smooth muscle cells (43),
indeed, the (pro)renin receptor was shown to be localized
mainly to the cytoplasm and sparsely to the cellular
surface, suggesting less efﬁcacy of PRRB exerted in vitro
than in vivo.
Recently, several studies have failed to show the inhib-
itory effect of PRRB on in vivo (44,45) and in vitro (46,47)
models. These negative data on PRRB were generated by
using in vivo (44,45) models in which the tissue RAS does
not originally play any role or in vitro (46,47) models
applied with too low concentration (1 mol/l) of PRRB.
The glomerulosclerosis in the clipped kidney in the rat
model of 2-kidney, 1-clip hypertension has already been
shown to be ischemic lesion resistant to RAS inhibition
(48). The dTG rats overexpressing human renin and angio-
tensinogen exhibited signiﬁcant increase in plasma renin
and angiotensin II (activation of the circulatory but not
tissue RAS), causing hypertension-induced cardiac and
renal damages (45). As expected, PRRB did not alter these
pathological conditions as a result of tissue RAS-indepen-
dent mechanisms (44,45).
Although hypertension is a known risk factor for the
progression of diabetic retinopathy (49,50), there are
indeed a large number of normotensive patients with
diabetic retinopathy who have the potential risk of hypo-
tension caused by the use of antihypertensive agents
including AT1-R blockers and ACE inhibitors. In contrast,
because the (pro)renin receptor is present in the major
organs but not in the circulation, PRRB does not affect the
circulatory RAS or systemic blood pressure (9,10). Inter-
estingly, PRRB administration to the diabetic retina was
shown to cause not only tissue RAS deactivation but also
additional suppression of (pro)renin receptor signaling–
mediated expression of VEGF—the major pathogenic factor
responsible for the development of diabetic retinopathy
(Fig. 8). Collectively, inhibition of the RAPS with PRRB
may prove more useful as a novel therapeutic strategy for
diabetic retinopathy than RAS suppression with conven-
tional AT1-R blockers or ACE inhibitors.
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